IL6 and cancer: In addition, the IL-6 and VEGF secretions of modified HSCs with TU-100 treatment were measured in the same dose dependent manner and it was confirmed that the TU-100 (270, 900) treatment could downregulate IL-6 and VEGF secretions from modified HSCs, compared to cancer-CM alone (Figure 1E).